Filing Details
- Accession Number:
- 0000899243-19-027545
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-18 17:43:33
- Reporting Period:
- 2019-11-14
- Accepted Time:
- 2019-11-18 17:43:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1629137 | Global Blood Therapeutics Inc. | GBT | Pharmaceutical Preparations (2834) | 274825712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1789673 | Joshua Lehrer-Graiwer | C/O Global Blood Therapeutics, Inc. 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-11-14 | 329 | $20.00 | 329 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-14 | 329 | $50.01 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 313 | $12.95 | 313 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 1,109 | $19.89 | 1,422 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 3,516 | $27.90 | 4,938 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 118 | $20.00 | 5,056 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 298 | $19.89 | 5,354 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-11-15 | 4,594 | $26.90 | 9,948 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-11-15 | 9,948 | $50.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-14 | 329 | $0.00 | 329 | $20.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 313 | $0.00 | 313 | $12.95 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 1,109 | $0.00 | 1,109 | $19.89 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 3,516 | $0.00 | 3,516 | $27.90 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 118 | $0.00 | 118 | $20.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 298 | $0.00 | 298 | $19.89 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-15 | 4,594 | $0.00 | 4,594 | $26.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 565 | 2025-08-10 | No | 4 | M | Direct | |
| 937 | 2025-03-04 | No | 4 | M | Direct | |
| 5,454 | 2026-09-07 | No | 4 | M | Direct | |
| 8,984 | 2027-07-25 | No | 4 | M | Direct | |
| 447 | 2025-08-10 | No | 4 | M | Direct | |
| 5,156 | 2026-09-07 | No | 4 | M | Direct | |
| 12,469 | 2027-02-16 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.045 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents the weighted average sale price of the shares sold ranging from $50.00 to $50.02 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares of Common Stock underlying this option are fully vested.
- The shares of Common Stock underlying this option vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from July 26, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
- The shares of Common Stock underlying this option shall vest in 16 equal quarterly installments over 4 years from February 17, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Billionaire Hedge Funds
